Gara Jalqabaatti › Dhibee Qara › California › San Francisco
Qorannoo klinikaalii Dhibee Qara San Francisco, CA keessatti
Qorannoo 22 Dhibee Qara f San Francisco fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of ZW251 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Namoota walitti qabaa jiraSadarkaa 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente-San Francisco, San Francisco
Smoking Cessation CM for Veterans With or at Risk for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- San Francisco VA Medical Center, San Francisco, CA, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Namoota walitti qabaa jira
- Kaiser Permanente-San Francisco, San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Namoota walitti qabaa jiraSadarkaa 3
- San Francisco Oncology Associates ( Site 0066), San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- University of California, San Francisco (UCSF), San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Namoota walitti qabaa jiraSadarkaa 3
- UCSF Medical Center-Mission Bay, San Francisco
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- California Pacific Medical Center-Pacific Campus, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Namoota walitti qabaa jiraSadarkaa 1/2
- UCSF Medical Center - Mission Bay, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2/3
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Namoota walitti qabaa jira
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Namoota walitti qabaa jiraSadarkaa 1/2
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, San Francisco
Qorannoo Dhibee Qara magaalota biroo keessatti
- Houston, TXQorannoo 78
- Boston, MAQorannoo 62
- New York City, NYQorannoo 60
- Los Angeles, CAQorannoo 45
- Arlington, VAQorannoo 41
- Washington, DCQorannoo 41
- Chicago, ILQorannoo 41
- Baltimore, MDQorannoo 40
- Nashville, TNQorannoo 40
- St. Louis, MOQorannoo 39
- Columbus, OHQorannoo 37
- Philadelphia, PAQorannoo 36
Qorannoo biroo San Francisco keessatti
- Kansarii ProstateQorannoo 45
- Saree OljooQorannoo 43
- Kansara Qara'a Non-Small CellQorannoo 36
- Saree (Gosoota Hunda)Qorannoo 35
- Cufama OnneeQorannoo 29
- Kansara MetastatikiiQorannoo 28
- MelanomaQorannoo 22
- Kansarii PancreasQorannoo 20
- Kansarii OvariiQorannoo 19
- Kansarii ColorectalQorannoo 18
- Dhibee Onneessaa fi DhiigaQorannoo 18
- GlioblastomaQorannoo 17
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.